PRAX News and Press, Praxis Precision Medicines Inc. From 02/23/26

2026-02-23 13:49:01 ET On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 437,000 Praxis Precision Medicines (NASDAQ:PRAX) shares, estimated at $81.38 million based on quarterly average pricing. According to a recent SEC filing , Baker Bros. Advisors increased ...

2026-02-19 16:15:05 ET Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call February 19, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript

2026-02-19 10:13:09 ET Image source: The Motley Fool. Thursday, Feb. 19, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-19 07:37:30 ET More on Praxis Precision Medicines Praxis: Priced For Perfection Heading Into 2026 Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET ...

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the  U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutr...

Travere Therapeutics Inc. (TVTX) is expected to report $0.03 for Q4 2025 Teck Resources Ltd (TECK) is expected to report $0.59 for Q4 2025 Heidmar Maritime Holdings Corp. (HMR) is expected to report $0.05 for Q4 2025 Endava plc American Depositary Shares (each representing one Class A...

2026-02-18 12:41:26 ET More on Praxis Precision Medicines Praxis: Priced For Perfection Heading Into 2026 Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET ...

2026-02-14 11:18:41 ET On February 13, 2026, Affinity Asset Advisors disclosed a new position in Praxis Precision Medicines (NASDAQ:PRAX) , acquiring 185,000 shares in an estimated $54.53 million trade. According to a SEC filing dated February 13, 2026, Affinity Asset Adviso...

2026-02-13 07:54:09 ET On Feb. 12, Soleus Capital Management, L.P. disclosed a buy of 629,398 shares of Celcuity (NASDAQ:CELC) in a Securities and Exchange Commission (SEC) filing Celcuity is a clinical-stage biotechnology firm focused on innovative cancer diagnostics and ta...

2026-02-10 16:15:00 ET Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to b iotech ETFs, they give sector participants exposure to many biotech companies via one vehicle. ETFs are a popular choice as they allow ...